N-[2-(4-Fluorophenyl)ethyl]phthalimide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-[2-(4-Fluorophenyl)ethyl]phthalimide
• 英文别名: 2-[2-(4-Fluorophenyl)ethyl]isoindole-1,3-dione
• 化学式: C₁₆H₁₂FNO₂
• 分子量: 269.275
• InChiKey: PTIJQDNAPSCQKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[2-(4-Fluorophenyl)ethyl]phthalimide 在 肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 4-氟苯乙胺
  参考文献：
  名称：

  Structure−Activity Relationships in the Binding of Chemically Derivatized CD4 to gp120 from Human Immunodeficiency Virus

  摘要：

  The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp 120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp 120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp 120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

  DOI：

  10.1021/jm070564e
• 作为产物：
  描述：

  4-氟溴乙基苯 、 potassium phtalimide 在 四丁基碘化铵 作用下， 以 二甲基亚砜 为溶剂， 反应 5.0h， 生成 N-[2-(4-Fluorophenyl)ethyl]phthalimide
  参考文献：
  名称：

  Structure−Activity Relationships in the Binding of Chemically Derivatized CD4 to gp120 from Human Immunodeficiency Virus

  摘要：

  The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp 120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp 120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp 120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

  DOI：

  10.1021/jm070564e

文献信息

• Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie Fluor enthaltende Beta-Iminovinyl- und Beta-Iminoethylbenzole
  申请人：Bayer Aktiengesellschaft

  公开号：EP1013637A2

  公开（公告）日：2000-06-28

  Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen, das dadurch gekennzeichnet ist, daß man in einer ersten Stufe ein substituiertes Brombenzol mit einem N-Vinylimid in Gegenwart eines Palladiumkatalysators umsetzt, in einer zweiten Stufe das erhaltene substituierte β-Iminovinylbenzol katalytisch hydriert und in einer dritten Stufe das in der zweiten Stufe erhaltene substituierte β-Iminoethylbenzol spaltet. Mit diesem Verfahren werden auch neue β-Iminovinyl- und β-Iminoethylbenzole zugänglich.

  本发明涉及一种制备含氟苯乙胺的工艺，其特征在于：第一阶段，在钯催化剂存在下，取代的溴苯与N-乙烯亚胺反应；第二阶段，对得到的取代的β-亚氨基乙烯基苯进行催化氢化；第三阶段，对第二阶段得到的取代的β-亚氨基乙烯基苯进行裂解。这一过程还可以获得新的β-亚氨基乙烯基苯和β-亚氨基乙基苯。
• CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE
  申请人：Cytokinetics, Inc.

  公开号：EP3127540A1

  公开（公告）日：2017-02-08

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、R4、R5、R6、R7、R8、R9、X 和 m 如本文所定义。 还提供了一种药学上可接受的组合物，包含式 I 的化合物或其药学上可接受的盐。 还提供了使用式I化合物或其药学上可接受的盐的方法。
• CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE
  申请人：Cytokinetics, Inc.

  公开号：EP3127541A1

  公开（公告）日：2017-02-08

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、R4、R5、R6、R7、R8、R9、X 和 m 如本文所定义。 还提供了一种药学上可接受的组合物，包含式 I 的化合物或其药学上可接受的盐。 还提供了使用式I化合物或其药学上可接受的盐的方法。
• US6232475B1
  申请人：——

  公开号：US6232475B1

  公开（公告）日：2001-05-15